Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab + Gemcitabine in Platinum-Resistant Ovarian Cancer
NCT00096993Phase 2Completed
- Sponsor
- Genentech
- Start
- Jan 2005
- Primary completion
- Sep 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Placebo + gemcitabine with Pertuzumab + gemcitabine (2 arms). Primary endpoint: Progression-free Survival at 1 year. Started Jan 2005; status: completed.
02
Drugs
pertuzumab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00096993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096993.